Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsDivislaboratories

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Super Six stocks you can bet on Dec 28

      On CNBC-TV18's show Super Six, market gurus Hemen Kapadia CEO chartpundit.com, Vishal B Malkan, CMT, www.malkansview.com and Nooresh Mirani - AVP Technical, AMSEC Research, place their bets on two stocks each, thus offering investors a variety of options to choose from.

    • Bull's Eye: Short Kingfisher, RCom; buy GMDC, United Phosp

      Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.

    • Buy Divis Laboratories: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can buy Divis Laboratories.

    • Buy Cipla, Divis Labs: Angel Broking

      Shardul Kulkarni of Angle Broking is bullish on Cipla and Divis Labs and bearish on Aban Offshore and Sintex Industries.

    • Divis Lab has target of Rs 1050: PN Vijay

      Divis Laboratories has target of Rs 1050 in the next 12-18 months, says PN Vijay, Portfolio Manager.

    • Divis Laboratories can touch Rs 1050: Jani

      Divis Laboratories can touch Rs 1050, says Hemang Jani of Sharekhan.

    • Buy Divis Laboratories: Parag Doctor

      Buy Divis Laboratories, says Parag Doctor of Motilal Oswal Securities.

    • Super Six: What's hot on the charts, and what's not

      On CNBC-TV18's new show Super Six, market gurus Hemen Kapadia, CEO of chartpundit.com, Parag Doctor of Motilal Oswal Securities and Shrikant Chouhan, VP Technical Research at Kotak Securities, place their bets on two stocks each, thus offering investors a variety of options to choose from.

    • Invest in Divis Labs at Rs 740-745: Daljit Singh Kohli

      Invest in Divis Labs at Rs 740-745, says Daljit Singh Kohli of Indianivesh.

    • Divis Lab has target of Rs 760: Nooresh Merani

      Divis Lab has target of Rs 760, says Nooresh Merani of AMSEC Research.

    • Buy Divis Lab, says Sanjay Vaid

      Buy Divis Lab, says Sanjay Vaid of SBI Capital.

    • Bull's Eye: 12 intraday picks for September 30

      Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.

    • Indian Bank may test Rs 212: Agarwal

      Indian Bank may test Rs 212, says Aditya Agarwal, Sr. Derivative Analyst, Way2Wealth.

    • Buy Divis Laboratories: Sanjay Vaid

      Buy Divis Laboratories, says Sanjay Vaid of SBI Capital Securities.

    • Bull's Eye: 12 trading picks for the day

      Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.

    • Divis Laboratories has target of Rs 855: Nooresh Mirani

      Divis Laboratories has target of Rs 855, says Nooresh Mirani, AVP Technical of AMSEC Research.

    • Bull's Eye: 12 trading picks for short term

      Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.

    • Divis Lab has target of Rs 1047: Hemang Jani

      Divis Laboratories has target of Rs 1047, says Hemang Jani, Sr Vice President, Sharekhan.

    • Pharma stocks look good: Sekhar

      Pharma stocks look good, says Phani Sekhar, Fund Manager, Angel Broking.

    • Divis Labs can touch Rs 825-828: Hemant Thukral

      Hemant Thukral, Head-Derivatives Research at SBI Capital Securities is of the view that Divis Laboratories can touch Rs 825-828.

    • Buy Divis Laboratories: Gaurang Shah

      Buy Divis Laboratories, says Gaurang Shah of Geojit BNP Paribas Fin Services.

    • Bull's Eye: What's hot on the charts, and what's not

      Bull's Eye, the popular game show on CNBC-TV18, offer investors a chance to have a look at the stocks that can be added to their portfolio.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347